ArticleBlood cancer journal2015
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.
Article in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Molecular and immunological determinants of long-term survival in multiple myeloma.Blood advances · 2025Review
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.American journal of hematology · 2024Review
- The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients.Frontiers in oncology · 2023Article
- High or low? Assessing disease risk in multiple myeloma.Hematology. American Society of Hematology. Education Program · 2022Article
- Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias.BMC medical genomics · 2022Article
- Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia.Current oncology (Toronto, Ont.) · 2022Article
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.American journal of hematology · 2022Article
- Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.Frontiers in oncology · 2022Review
- Prognostic and predictive biomarker developments in multiple myeloma.Journal of hematology & oncology · 2021Review
- Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.Journal of medical case reports · 2020Review
- Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.British journal of haematology · 2019Article
- Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.Blood cancer journal · 2019Article
- Review
- Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementAmerican journal of hematology · 2018Article
- The multiple myelomas - current concepts in cytogenetic classification and therapy.Nature reviews. Clinical oncology · 2018Review
- A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.Blood cancer journal · 2016Article
- Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.American journal of hematology · 2016Review
- Myeloma today: Disease definitions and treatment advances.American journal of hematology · 2016Review
- Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?OncoTargets and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
We studied all patients at our institution with a diagnosis of multiple myeloma (MM), from 1 January 2004 to 1 July 2009, who received lenalidomide-dexamethasone (Rd) as initial therapy and had a time to progression of 72 months or longer. Of 240 patients, we identified 33 exceptional responders. Twenty-five patients received primary therapy with Rd and eight patients received Rd induction followed by early stem cell transplantation (SCT). Seven of the eight patients who received SCT did not receive maintenance therapy; one patient received 9 months of lenalidomide post transplant. Fifteen (45%) patients had known clonal plasma cell disorder before the diagnosis of MM. The dominant mode of clinical presentation was with lytic lesions in 28 patients. Of those with informative cytogenetics (n=24), trisomies were present in 19 (79%), including one patient with concurrent trisomies and t(11;14). Overall, 21 of 24 patients (88%) had either trisomies or t(11;14). None of these exceptional responders had high-risk cytogenetic features at baseline. Twenty-five patients (76%) had a complete response (CR), whereas eight patients (24%) achieved the exceptional response state without ever achieving a CR. We identify a cohort of exceptional responders to Rd-based therapy, representing ~10-15% newly diagnosed MM patients with normal renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.